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domized, controlled investigations with a sufficient number of
patients are needed. However, the general public and the medical
community should be reassured by our study that the severity of
the problem is probably much less than initially thought.
Andrew J. Burger, MD
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Risk of Neutropenia With Clopidogrel
Dr. Berger et al. presented a cogent comparison of ticlopidine and
clopidogrel after intracoronary artery stent placement (1). How-
ever, they present misleading information regarding the side effects
of clopidogrel. They state, “Clopidogrel does not cause neutrope-
nia . . . ” (1). The authors use the CAPRIE trial as a supporting
reference. In the CAPRIE trial “ . . . the numbers for low neutro-
phil counts were ten (0.10%) and 16 (0.17%) (clopidogrel and
aspirin groups, respectively). Among these latter cases, the neu-
trophil count fell below 0.45 3 10ˆ9/L for five (0.05%) and four
(0.04%) patients in the clopidogrel and aspirin groups, respective-
ly., . . . In CAPRIE, there was no excess neutropenia in the
clopidogrel group (2).” Hence, more appropriately, the authors
should have stated that the risk of neutropenia is less than with
ticlopidine but essentially equivalent to aspirin.
It is important for cardiologists to remember that clopidogrel
can be associated with neutropenia, albeit very infrequently.
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We appreciate Dr. Dieter’s interest in our article and the oppor-
tunity to respond to his letter. Patients in CAPRIE were inten-
sively monitored for neutropenia, and severe neutropenia (,450
per microliter) was observed in six patients, four of whom were
receiving clopidogrel (three women, one man, all of whom were
Caucasian). Although these patients did develop neutropenia while
receiving clopidogrel, we disagree with Dr. Dieter’s conclusion that
clopidogrel “caused” the neutropenia in these patients. One patient
was receiving chemotherapy for a malignancy when the neutrope-
nia occurred. Two patients developed only transient neutropenia,
which did not resume after clopidogrel was reinitiated, and they
continued to receive clopidogrel for the duration of the study. We
should mention that a fifth clopidogrel patient was described in the
CAPRIE manuscript as having developed neutropenia but was
found to have aplastic anemia and was, therefore, not considered
by the Food and Drug Administration to have developed “neutro-
penia.” This fifth clopidogrel patient does not appear in the
labeling for clopidogrel. (Similarly, two additional aspirin patients
were described in the CAPRIE manuscript as having developed
neutropenia; one had actually developed acute myelogenous leu-
kemia, and one was found to have been neutropenic at study
entry.)
Despite the “association” between clopidogrel and neutropenia
in these four patients, we are no more convinced that clopidogrel
caused their neutropenia than we are convinced that aspirin caused
the neutropenia in the two patients in the aspirin group. It is
important to distinguish between the frequency of “background”
Table 1.
Mitral Regurgitation Aortic Regurgitation
Age Men Women Men Women Men Women
26–39 0.186 0.142 0 0 0 0
40–49 0.302 0.361 0.003 0.009 0.017 0.007
50–59 0.442 0.383 0.016 0.01 0.042 0.021
60–69 0.07 0.115 0.024 0.023 0.127 0.068
70–83 0 0 0.112 0 0.144 0.169
.83 0 0 0.112 0 0.144 0.169
Expected prevalence 0.010 0.010 0.033 0.018
Total expected prevalence 0.010 0.021
Observed prevalence 0.013 0.066
Prevalence ratio 1.34 3.13
95% confidence limits 0.41–4.35 0.99–9.85
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neutropenia or neutropenia from other causes among patients
taking clopidogrel in CAPRIE from the neutropenia seen in .1%
of patients treated with ticlopidine for greater than 1 month in
whom profound life-threatening neutropenia develops requiring
cessation of the drug and often requiring therapeutic interventions.
This sort of severe neutropenia did not occur in any of the more
than 9,000 patients in CAPRIE treated with clopidogrel and has
been reported very rarely in the greater than 4 million people
treated with clopidogrel since the drug was approved for use in the
United States based on post-market surveillance (Dr. Melvin
Blumenthal, MD, Bristol-Myers Squibb, personal communication).
In conclusion, the frequency of neutropenia among patients
taking clopidogrel appears to be similar to the background occur-
rence of neutropenia in patients taking aspirin, and the evidence
from CAPRIE and all other randomized trials suggests clopidogrel
does not cause neutropenia, as we stated in the article.
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Improvement of Myocardial
Blood Flow to Ischemic Regions by
Angiotensin-Converting Enzyme Inhibition
Schneider et al. (1) analyzed the effects of acute angiotensin-
converting enzyme (ACE) inhibition on myocardial blood flow
(MBF) in ischemic and nonischemic regions of 10 symptomatic
patients with coronary artery disease (CAD). They used [15O] water
positron emission tomography at rest and during maximal dobut-
amine stress before and after angiotensin converting enzyme (ACE)
inhibition and demonstrated that quinaprilat 10 mg intravenous was
able to improve MBF to ischemic regions in patients with CAD.
There is some experimental and clinical evidence that ACE
inhibitors can increase regional oxygen supply to ischemic areas of
myocardium through a redistribution of regional blood flow in
humans and animals (2–7). However, there is not evidence that
ACE-inhibitors are able to improve the main clinical outcomes in
evaluation of anti-ischemic efficacy of cardiovascular drugs as
angina, ST segment depression and echocardiographic wall motion
abnormalities during exercise or pharmacological stress test. In this
regard we demonstrated, using exercise and dipyridamole echocar-
diographic stress tests, that neither captopril nor enalapril (sulfhy-
dryl and not sulfhydryl ACE-inhibitors, respectively) had a signif-
icant antiischemic effect in patients with stable angina pectoris (8).
In our point of view, the main questions are: Has the improve-
ment of MBF induced by acute administration of quinaprilat a
clinical significance? Is it useful to evaluate the effects of a
cardiovascular drug by an advanced technique as [15O] water
positron emission tomography without the evidence of clinical,
mechanical or electrocardiographic markers of myocardial ischemia
in all patients during stress test?
Analyzing the methods used by authors (1), we found that most
patients did not have clinical, electrocardiographic or mechanical
criteria of ischemia during dobutamine stress test. Therefore, there
is not evidence in the results section that the quinaprilat is able to
reduce myocardial ischemia. This restricts the relevance of the
conclusions for the average clinical reader. We think that the
quinaprilat-induced changes in MBF are not enough to establish
whether ACE-inhibitors are the anti-ischemic drugs or not.
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We appreciate the interest of Dr. Langobardi and his colleagues
concerning our analysis of the antiischemic effect of 10 mg
quinapril (intravenous) assessed by 15O water positron emission
tomography (PET) (1) and questioning the clinical value of our
observation. The clear advantage of the PET technique we have
used is the noninvasive, quantitative analysis of changes in regional
myocardial blood flow, which is currently only possible with
positron tracers. Using this technique a significant improvement in
myocardial blood flow after quinaprilat intravenous could be
demonstrated. We agree with Dr. Langobardi that the incidence of
clinical signs of ischemia was low in our patient population as it was
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